indantadol

Indantadol is a small molecule drug that was developed as an oral agent for the treatment of neuropathic pain and chronic cough. It acts as a competitive, reversible, and non-selective inhibitor of monoamine oxidase A (MAO-A), leading to increased levels of neurotransmitters such as serotonin, dopamine, and norepinephrine. Additionally, it functions as a low-affinity, non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor. This dual mechanism provides both neuroprotective effects and modulation of pain perception. Indantadol was investigated in phase II clinical trials for diabetic peripheral neuropathic pain and chronic cough but failed to show significant efficacy in some studies; development has since been discontinued[1][4][5][7].

Other names

indantadol hydrochloride2-(2,3-dihydro-1H-inden-2-ylamino)acetamide